Quantcast

Industry news that matters to you.  Learn more

Abcodia and BIOUNIVERSA Announce Collaboration on BAG3 Biomarker for the Early Detection of Pancreatic Cancer

Reading time: 2 minutes

Abcodia, a biomarker validation company, has today announced a collaboration with BIOUNIVERSA Srl, a spin off from the University of Salerno, which aims to advance the development of the BAG3 protein biomarker for use in the early detection of pancreatic cancer.

BIOUNIVERSA has strong scientific evidence that suggests that serum BAG3 is elevated in patients with pancreatic cancer at the time of clinical diagnosis. Working with Abcodia, the company now aims to further develop the BAG3-based immunodiagnostic by assessing its utility for detecting pancreatic cancer at the earliest stages and in asymptomatic individuals.

Abcodia and BIOUNIVERSA will work closely to design a series of longitudinal studies, identify preclinical cohort samples from the serum biobank suitable for the evaluation of BIOUNIVERSA BAG3 ELISA assay, a technology that has been developed by Prof M.C. Turco and her group from University of Salerno, coordinated by the Prevost, Prof. Raimondo Pasquino. The collaboration aims to build up a unique package of data that will support the licensing of the IP to a development partner. Both Abcodia and BIOUNIVERSA will work in partnership to identify the most suitable licensee.

Julie Barnes, Chief Executive for Abcodia, said: “I am delighted to be able to announce this commercial collaboration with BIOUNIVERSA. This company has developed a proprietary position on BAG3 and I hope that our partnership will advance that position significantly by assessing how early BAG3 can be detected before clinical diagnosis.”

Professor Roberto Parente, VP of External Relations at BIOUNIVERSA and Professor of Management at the University of Salerno, said: “This collaboration with Abcodia provides access to thousands of quality serum samples, expertise in longitudinal designs and importantly links with other commercial companies. Without access to this cohort of longitudinal and preclinical samples, the further development of our technology would take several years and a large financial commitment. With Abcodia, we are hopeful to accelerate our development and seek a commercial licensee over the next 12 months.”

Financial details were not disclosed.

Source: Abcodia